stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Return on assets
Pfizer Inc.'s return on assets over the twelve months to 30 September 2026 was 1.95%, down 1.7 percentage points from fiscal 2025 (3.69%). Over the past ten years it has ranged from 1.00% (fiscal 2023) to 16.6% (fiscal 2022); the current reading is higher than 27% of that period. That is below the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 3.69% | 0.04 |
| FY2024 | 3.65% | 2.65 |
| FY2023 | 1.00% | (15.57) |
| FY2022 | 16.6% | 3.48 |
| FY2021 | 13.1% | 7.40 |
| FY2020 | 5.69% | (4.11) |
| FY2019 | 9.80% | 3.07 |
| FY2018 | 6.73% | (5.68) |
| FY2017 | 12.4% | 8.15 |
| FY2016 | 4.26% | 0.10 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi compare | 3.24% |
| PFE Pfizer Inc. | 1.95% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement